An interventional study of Dietary macronutrient composition in Diabetes Mellitus, Type 2, Overweight and Obesity and Metabolic Syndrome, sponsored by Hvidovre University Hospital. Recruiting at 1 site in Denmark. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Hvidovre University Hospital · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Diabetes Mellitus, Type 2 by Hvidovre University Hospital — 1 open to participants now, 1 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Hvidovre University Hospital.
Among the 12 studies in Diabetes Mellitus, Type 2 by Hvidovre University Hospital, this one is the only one that started in 2024, is one of 7 with no phase, and was the 12th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 12 studies in Diabetes Mellitus, Type 2 by Hvidovre University Hospital is open now, in 1 country.
By country, each count listing its studies:
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 35 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 11 is below the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 11 across the 7 interventional studies, 24 across the 5 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hvidovre University Hospital is the lead sponsor of 299 studies on the registry; 20 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Diabetes Mellitus, Type 2 by Hvidovre University Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary aim of this randomized cross-over intervention study is to investigate the effect of 16 days of intermittent carbohydrate restriction (alternating between two days of a conventional control diet and, two days of carbohydrate restriction to 10E% (\~70-90 grams)) on 24-hour average sensor glucose (primary outcome) in individuals with type 2 diabetes compared with a 16 day control period with a conventional diet. 24-hour average sensor glucose is measured by patient-blinded continuous glucose monitoring (CGM) during the intervention and control period.
The criteria were revised on the registry on Nov 16, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
16 days of intermittent carbohydrate restriction: a controlled dietary regime alternating between two days of restricting carbohydrate intake to 70-90 grams, and two days of a conventional control diet. Protein content is matched between diets. All food is provided.
Other: Dietary macronutrient composition
During the control period (16 days) the macronutrient composition matches that of the non-carbohydrate-restricted days of the intermittent carbohydrate intervention.
Intermittent carbohydrate restriction
24-hour average sensor glucose
A patient-blinded continuous glucose monitoring (CGM) is worn during the 16 day intervention and control period.
Time frame: 24-hour average sensor glucose is measured as the average of eight consecutive days (starting from two days post sensor mounting).
Fasting plasma concentrations of triacylglycerols
Fasting plasma concentrations of triacylglycerols measured on the day before and the day after the dietary intervention (i.e. day 0 and day 18) and on the day before and the day after the control period (i.e. day 0 and day 18).
Time frame: day 18 adjusted for baseline
Explorative outcomes - Questionnaires on quality of life
Participants will complete the questionnaires 'Problem Areas In Diabetes' \& 'World Health Organisation-Five Well-Being Index'.
Time frame: day 18
Explorative outcomes - Qualitative evaluation to assess feasibility of the dietary strategy
A semi-structured evaluation interview to assess social context, eating practices, compliance to, and feasibility and acceptability of the intermittent carbohydrate restriction regime will be carried out.
Time frame: day 18
Started Jan 2024 (actual). Primary completion is estimated for Dec 2027, 46 months after the start.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 46 months is above that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Sep 2025 → Dec 2027 and completion Sep 2025 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hvidovre University Hospital →